2 results
Approved WMOCompleted
Primary objective is to assess in vivo neuroinflammation quantitatively in patients with sepsis. Secondary objective is to study whether differences in in vivo neuroinflammation are related to long term cognitive outcomes.
Approved WMORecruiting
Objective: To compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, withrespect to progression-free survival (PFS) per RECIST 1.1 as assessed by the investigator.